Scott Edwards

Dr. Scott Edwards Pharm D, MSc (Oncol) is the Clinical Oncology Pharmacy Specialist with the Cancer Care Program in St. John's, Newfoundland and Assistant Professor with Memorial University. He completed a Bachelor of Neuroscience and Pharmacy at Memorial. He completed his Doctor of Pharmacy degree from the University of Washington. He completed a Master's degree in Oncology from Newcastle University.
He is active in research in the area of anti-cancer agent toxicities and supportive care.
He is passionate about teaching both undergraduate and postgraduate students.

Current Position
Clinical Pharmacy Specialist, Cancer Care Program, Eastern Health. St. John’s, NL
Clinical Assistant Professor Oncology, Faculty of Medicine and School of Pharmacy, Memorial University of Newfoundland, St. John’s, NL

Training
Masters in Oncology, Newcastle University, Newcastle, England
Doctor of Pharmacy. University of Washington, Seattle, Washington, USA.
Bachelor of Science (Pharmacy). Memorial University of Newfoundland, St. John’s, NL
Bachelor of Science (Neuroscience). Memorial University of Newfoundland, St. John’s, NL

Publications

Jerzak, K. J., Sehdev, S., Boileau, J.-F., Brezden-Masley, C., Califaretti, N., Edwards, S., Gordon, J., Henning, J.-W., LeVasseur, N., & Railton, C. (2025). Multidisciplinary practical guidance for implementing adjuvant CDK4/6 inhibitors for patients with HR-positive, HER2-negative early breast cancer in Canada. Current Oncology, 32(8), 444.

McFarlane, T., Sothilingam, R., Fernandes, O., Houle, S. K. D., Lo, J., Abadi, S., Edwards, S., LeBlanc, M., Wentzell, J., Tibensky, B., DeAngelis, C., & Steeves, L. (2025). Development of ambulatory oncology clinical pharmacy key performance indicators using a modified Delphi consensus approach. JCO Oncology Practice. Advance online publication.

Chan, A., Nixon, N., Al-Khaifi, M., Bestavros, A., Blyth, C., Cheung, W. Y., Hamm, C., Joly-Mischlich, T., Manna, M., McFarlane, T., Minard, L. V., Naujokaitis, S., Peragine, C., Railton, C., & Edwards, S. (2025). Optimizing adjuvant care in early breast cancer: Multidisciplinary strategies and innovative models from Canadian centers. Current Oncology, 32(7), 402.

Manna, M., Gelmon, K. A., Boileau, J.-F., Brezden-Masley, C., Cao, J. Q., Jerzak, K. J., Prakash, I., Sehdev, S., Simmons, C., Bouganim, N., Brackstone, M., Cescon, D. W., Chia, S., Dayes, I. S., Edwards, S., Hilton, J., Joy, A. A., Laing, K., Webster, M., & Henning, J.-W. (2024). Guidance for Canadian breast cancer practice: National consensus recommendations for the systemic treatment of patients with HER2+ breast cancer in both the early and metastatic setting. Current Oncology, 31(11), 6536–6567.

Leblanc, K., Edwards, S., Ewards, J., Dranitsaris, G., Leong, D. P., Carrier, M., Malone, S., Rendon, R. A., Bond, A. M., Sitland, T. D., Zalewski, P., Wang, M., & Emmenegger, U. (2024). Drug interactions between androgen receptor axis-targeted therapies and antithrombotic therapies in prostate cancer: Delphi consensus. Cancers, 16(19), 3336.

Sehdev, S. R., Rawson, N. S. B., Aseyev, O. I., Buick, C. J., Butler, M. O., Edwards, S., Gill, S., Gotfrit, J. M., Hsia, C. C., Juergens, R. A., Manna, M., McCarthy, J. S., Mukherjee, S. D., Snow, S. L., Spadafora, S., Stewart, D. J., Wentzell, J. R., Wong, R. P. W., & Zalewski, P. G. (2024). Access to oncology medicines in Canada: Consensus forum for recommendations for improvement. Current Oncology, 31(4), 1803–1816.

Jerzak, K. J., Bouganim, N., Brezden-Masley, C., Edwards, S., Gelmon, K., Henning, J.-W., Hilton, J. F., & Sehdev, S. (2023). HR+/HER2– advanced breast cancer treatment in the first-line setting: Expert review. Current Oncology, 30(6), 5425–5447.

Canadian Association of Nurses in Oncology (CANO). (2022). Clinical practice resource: FGFR inhibitor therapy (pemigatinib and infigratinib) in patients with advanced cholangiocarcinoma. CANO endorsed resource.

Tibensky, B., Hutton, L., Wentzell, J., LeBlanc, M., Edwards, S., & McFarlane, T. (2022). Clinical pharmacy services in ambulatory oncology: An environmental scan of the Canadian practice landscape. Canadian Journal of Hospital Pharmacy, 75(4), 259–266.

Walsh, F., Wall, A., Abbott, R., & Edwards, S., (2020). The institutional challenges of implementing an oncology therapeutic biosimilar in a Canadian cancer center and the case for a biosimilar pharmacist. Journal of Oncology Pharmacy Practice, 26(4 Suppl), 1.

Dent, S. F., Ammendolea, C., Christofides, A., Edwards, S., Incekol, D., Pourmirza, B., Kfoury, S., & Poirier, B. (2019). A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer. Current Oncology, 26(1), e70–e80.

Edwards, S. J., Abbott, R., & Dranitsaris, G. (2019). Patient monitoring programs in oncology pharmacy practice: A survey of oncology pharmacists in Atlantic Canada. Journal of Oncology Pharmacy Practice, 25(4), 891–895.

Edwards, S. (2018, June). Biosimilars: The role of the pharmacist. Biosimilars in Oncology.

Chia, S., Gandhi, S., Joy, A. A., Edwards, S., Gorr, M., Hopkins, S., Kondejewski, J., Ayoub, J. P., Califaretti, N., Rayson, D., & Dent, S. F. (2015). Novel agents and associated toxicities of inhibitors of the PI3K–Akt–mTOR pathway for the treatment of breast cancer. Current Oncology, 22(1), 33–48.

Kanji, S., Hayes, M., Ling, A., Shamseer, L., Chant, C., Edwards, D. J., Edwards, S.,  Ensom, M. H. H., Foster, D. R., Hardy, B., Kiser, T. H., la Porte, C., Roberts, J. A., Shulman, R., Walker, S., Zelenitsky, S., & Moher, D. (2015). Reporting guidelines for clinical pharmacokinetic studies: The ClinPK statement. Clinical Pharmacokinetics, 54(7), 783–795.

Edwards, S. J., Abbott, R., Edwards, J., LeBlanc, M., Dranitsaris, G., Donnan, J., Laing, K., Whelan, M. A., & MacKinnon, N. J. (2014). Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinic. Journal of Pharmacy Practice, 27(1), 46–52.

Abbott, R., Edwards, S., Whelan, M., Edwards, J., & Dranitsaris, G. (2014). Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada. Journal of Oncology Pharmacy Practice, 20(1), 29–39.

Abbott, R., Edwards, S., Edwards, J., Dranitsaris, G., & McCarthy, J. (2011). Oral anti-cancer agents in the community setting: A survey of pharmacists in Newfoundland and Labrador. Canadian Pharmacists Journal, 144(5), 220–226.

Dranitsaris, G., Edwards, S., Edwards, J., LeBlanc, M., & Abbott, R. (2010). Bevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: An assessment of safety and efficacy in the province of Newfoundland and Labrador. Current Oncology, 17(5), 12–16.

Edwards, J., Edwards, S., & Saltman, D. (2011). The role of the nurse practitioner and clinical pharmacist in collaborative patient care and drug therapy management in Canadian cancer centers. In Report Card on Cancer in Canada 2010–11 (pp. 30–33). Cancer Advocacy Coalition of Canada.

Awards